CCG-222740

Modify Date: 2025-08-25 12:44:31

CCG-222740 Structure
CCG-222740 structure
Common Name CCG-222740
CAS Number 1922098-69-8 Molecular Weight 444.86
Density N/A Boiling Point N/A
Molecular Formula C23H19ClF2N2O3 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of CCG-222740


CCG-222740 is a potent and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor[1]. CCG-222740 also is a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis[2].

 Names

Name CCG-222740

 CCG-222740 Biological Activity

Description CCG-222740 is a potent and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor[1]. CCG-222740 also is a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis[2].
Related Catalog
Target

Rho/MRTF pathway[1]

In Vitro CCG-222740 (10, 20 μM; for 72 hours) increases the protein levels of p27 and decreased cyclin D1. CCG-222740 decreases cell viability of CAFs, with an IC50 of ~10 μM[1]. CCG-222740 (10, 25 μM) is potent at decreasing αSMA protein expression in human conjunctival fibroblasts[2]. CCG-222740 has an IC50 of 5 μM in a fibroblast-mediated collagen contraction assay, and it is less cytotoxic[2]. Cell Cycle Analysis[1] Cell Line: Cancer associated fibroblasts (CAFs) Concentration: 10, 20 μM Incubation Time: 72 hours Result: Increased the protein levels of p27 and decreased cyclin D1.
In Vivo CCG-222740 (Oral gavage; 100 mg/kg daily for 7 days) significantly reduces α-SMA levels in the pancreas of caerulein-stimulated KC mice[1]. Animal Model: KC mice (LSL-KrasG12D/+; Pdx-1-Cre) of age at 9 weeks[1] Dosage: 100 mg/kg Administration: Oral gavage; daily; for 7 days Result: Reduced α-SMA levels in the pancreas of caerulein-stimulated KC mice.
References

[1]. Leal AS, et al. The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in KrasG12D; Pdx1-Cre (KC) mice. Sci Rep. 2019 May 8;9(1):7072.

[2]. Yu-Wai-Man C, et al. Local delivery of novel MRTF/SRF inhibitors prevents scar tissue formation in a preclinical model of fibrosis. Sci Rep. 2017 Mar 31;7(1):518.

 Chemical & Physical Properties

Molecular Formula C23H19ClF2N2O3
Molecular Weight 444.86
Storage condition -20°C
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here



Get all suppliers and price by the below link:

CCG-222740 suppliers

CCG-222740 price

Related Compounds: More...
ccg-9810
5524-60-7
4-[2-[(Z)-(3-bromo-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]hydrazinyl]-N-(2-methylphenyl)-4-oxobutanamide
6046-54-4
3-N,3-N,7-N,7-N,11-N,11-N,3,7,11-nonamethyl-1,2,5,6,9,10-hexathiacyclododecane-3,7,11-tricarboxamide
5119-37-9
CCG-273463
2750413-99-9
CCG-203586
1430611-24-7
CCG-271423
2750413-88-6
methyl 4-(4-hydroxy-3-nitrophenyl)-2-methyl-5-oxo-7-phenyl-4,6,7,8-tetrahydro-1H-quinoline-3-carboxylate
5476-43-7
ccg-7786
5377-87-7
ccg-2785
5637-01-4
5-(2-chlorophenyl)-2-methyl-N-(4H-1,2,4-triazol-3-yl)-1,3-thiazole-4-carboxamide
1574317-76-2
2-chloro-5-(1H-1,2,3,4-tetraazol-1-yl)-N-(2-[1,2,4]triazolo[4,3-a]pyridin-3-ylethyl)benzamide
1435984-95-4
N-{3-[2-(3,4-dimethoxyphenyl)ethyl]-1H-1,2,4-triazol-5-yl}-2-(5-methoxy-1H-indol-1-yl)acetamide
1441906-37-1
N-[4-oxo-3-(propan-2-yl)-3,4-dihydroquinazolin-6-yl]-6-(4-oxoquinazolin-3(4H)-yl)hexanamide
1574308-36-3
1-[(4-fluorophenyl)sulfonyl]-N-[1-(propan-2-yl)-1H-indol-4-yl]piperidine-4-carboxamide
1435908-27-2
3-[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-yl]-N-(6-methoxypyridin-3-yl)propanamide
1401559-50-9
methyl 5-methyl-2-({[1-(1H-tetrazol-1-yl)cyclohexyl]carbonyl}amino)-1,3-thiazole-4-carboxylate
1401569-42-3
2-Cyclobutyl-7-(2-fluoro-4-methoxyphenyl)[1,2,4]triazolo[1,5-a]pyrimidine
1574326-51-4
2-methyl-5-oxo-N-(3-pyridylmethyl)-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxamide
1435991-34-6
methyl N-{[2'-(2-methylpropyl)-1'-oxo-1',4'-dihydro-2'H-spiro[cyclohexane-1,3'-isoquinolin]-4'-yl]carbonyl}glycinate
1401530-00-4